Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: A prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

  • A. Du Bois
  • , J. Sehouli
  • , B. Lund
  • , F. Joly
  • , J. Huober
  • , T. S. Jensen
  • , E. Levy
  • , V. Heilmann
  • , K. Boman
  • , A. C. Hardy-Bessard
  • , A. Burges
  • , J. Mäenpää
  • , E. Pujade-Lauraine
  • , J. Pfisterer
  • , M. Gropp
  • , A. Staehle
  • , P. Wimberger
  • , C. Jackisch
  • , B. Schmalfeldt
  • , A. Belau
    • S. Loibl, K. Wollschlaeger, U. Canzler, J. Rochon

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: A prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science